Dimethyl fumarate (Tecfidera) in the treatment of multiple sclerosis

Dimethyl fumarate (Tecfidera) is an oral disease-modifying drug (Disease Modifying Therapy, DMT) for the oral treatment of multiple sclerosis (MS). Its main ingredient is dimethyl fumarate, a drug that modulates the immune system's response. Multiple sclerosis is a chronic inflammatory disease of the central nervous system characterized by an immune system attack on the myelin sheath, resulting in neuronal damage and a variety of neurological symptoms.

Clinical trial data show that Tecfidera has significant efficacy in slowing the progression of multiple sclerosis. Here are some key clinical study results and observations:

1.Reduced relapse rates: Multiple clinical trials have shown that patients taking Tecfidera had a significantly reduced risk of experiencing a relapse of multiple sclerosis compared with placebo or other treatment groups. Relapse usually manifests as new neurological symptoms or an exacerbation of existing symptoms.

2.Reduces disease activity: Tecfideranot only reduces clinically visible relapses, but also shows suppression of disease activity on magnetic resonance imaging (MRI). This includes reducing the formation of new brain lesions and shrinking the size of existing lesions, reflecting broad control of disease activity.

3.Improved quality of life: In addition to direct disease-modifying effects, Tecfidera has been associated with improved quality of life in patients with multiple sclerosis. Patients may experience less symptom exacerbation, improving their daily functioning and overall well-being.

4.Safety: Clinical trials and long-term monitoring of Tecfidera indicate that the drug is generally safe and well tolerated. Some patients may experience some mild gastrointestinal discomfort early in treatment, but these symptoms usually subside within a short period of time. In addition, Tecfidera's effects on blood cells and other important physiological parameters are generally controllable and reversible.

It is important to note that each patient's response may be different, and clinical trial data provide general trends but do not represent each patient's individual experience. Therefore, patients using Tecfidera or any other medication should do so under professional medical supervision and work closely with their doctor to ensure an individualized treatment plan. In addition, the medical field is constantly evolving and new research and data may exist, so it is recommended to stay informed of the latest clinical trial results.

The original drug of dimethyl fumarate has been launched in China and has been included in medical insurance. Patients can buy it domestically at a price of about 5,000 to 6,000 yuan. Please consult the local hospital pharmacy for specific prices. The main foreign drug is dimethyl fumarate original drug. The cheaper one is the Indian original drug, which costs more than 2,000 yuan and has the same composition and efficacy as the domestic original drug.